Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes

Faraz Razi,1 Adnaan Haq,2 Prabhu Tonne,3 Maharatnam Logendran3 1Department of Paediatrics, Basingstoke and North Hampshire Hospital, Basingstoke, UK; 2Department of Ophthalmology, Leicester General Hospital, Leicester, UK; 3Department of Ophthalmology, Northampton General Hospital, Northampton, UK...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Razi F, Haq A, Tonne P, Logendran M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Long-term results – Lucentis – Neovascular AMD Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/68d1772552b340c8941b672531224913
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:68d1772552b340c8941b672531224913
record_format	dspace
spelling	oai:doaj.org-article:68d1772552b340c8941b6725312249132021-12-02T04:10:36ZThree-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes1177-5483https://doaj.org/article/68d1772552b340c8941b6725312249132016-02-01T00:00:00Zhttps://www.dovepress.com/three-year-follow-up-of-ranibizumab-treatment-of-wet-age-related-macul-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Faraz Razi,1 Adnaan Haq,2 Prabhu Tonne,3 Maharatnam Logendran3 1Department of Paediatrics, Basingstoke and North Hampshire Hospital, Basingstoke, UK; 2Department of Ophthalmology, Leicester General Hospital, Leicester, UK; 3Department of Ophthalmology, Northampton General Hospital, Northampton, UK Purpose: To determine the effect of ranibizumab on visual acuity (VA) following a 3-year treatment period for patients diagnosed with wet age-related macular degeneration. To establish whether baseline VA and injection frequency influence visual outcomes. Patients and methods: Retrospective review of 70 patients (76 eyes) treated with 0.5 mg intravitreal ranibizumab for 3 consecutive months, and pro re nata thereafter (three + pro re nata protocol), over a 3-year period. VA was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts at baseline, 12, 24, and 36 months. The number of injections administered at the end of years 1, 2, and 3 were also recorded. Eyes were stratified according to baseline VA, as well as the number of injections administered at the end of year 1. Linear regression analysis determined the relationship between VA and both baseline VA and injection frequency. P<0.05 was considered statistically significant. Results: At 36 months, VA improved by a mean of 5.3 ETDRS letters (P=0.002), with 29% of eyes (n=22) demonstrating a clinically significant improvement in VA (gain of ≥15 ETDRS letters). Improvements in VA from baseline to 36 months were inversely proportional to the baseline VA (R=0.414, P=<0.001). A positive correlation was observed between injection frequency and change in VA from baseline to 36 months (R=0.244, P=0.036). Conclusion: Mean improvement in VA is inversely proportional to baseline VA, and directly proportional to injection frequency. Keywords: long-term results, Lucentis, neovascular AMDRazi FHaq ATonne PLogendran MDove Medical PressarticleLong-term results – Lucentis – Neovascular AMDOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 313-319 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Long-term results – Lucentis – Neovascular AMD Ophthalmology RE1-994
spellingShingle	Long-term results – Lucentis – Neovascular AMD Ophthalmology RE1-994 Razi F Haq A Tonne P Logendran M Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
description	Faraz Razi,1 Adnaan Haq,2 Prabhu Tonne,3 Maharatnam Logendran3 1Department of Paediatrics, Basingstoke and North Hampshire Hospital, Basingstoke, UK; 2Department of Ophthalmology, Leicester General Hospital, Leicester, UK; 3Department of Ophthalmology, Northampton General Hospital, Northampton, UK Purpose: To determine the effect of ranibizumab on visual acuity (VA) following a 3-year treatment period for patients diagnosed with wet age-related macular degeneration. To establish whether baseline VA and injection frequency influence visual outcomes. Patients and methods: Retrospective review of 70 patients (76 eyes) treated with 0.5 mg intravitreal ranibizumab for 3 consecutive months, and pro re nata thereafter (three + pro re nata protocol), over a 3-year period. VA was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts at baseline, 12, 24, and 36 months. The number of injections administered at the end of years 1, 2, and 3 were also recorded. Eyes were stratified according to baseline VA, as well as the number of injections administered at the end of year 1. Linear regression analysis determined the relationship between VA and both baseline VA and injection frequency. P<0.05 was considered statistically significant. Results: At 36 months, VA improved by a mean of 5.3 ETDRS letters (P=0.002), with 29% of eyes (n=22) demonstrating a clinically significant improvement in VA (gain of ≥15 ETDRS letters). Improvements in VA from baseline to 36 months were inversely proportional to the baseline VA (R=0.414, P=<0.001). A positive correlation was observed between injection frequency and change in VA from baseline to 36 months (R=0.244, P=0.036). Conclusion: Mean improvement in VA is inversely proportional to baseline VA, and directly proportional to injection frequency. Keywords: long-term results, Lucentis, neovascular AMD
format	article
author	Razi F Haq A Tonne P Logendran M
author_facet	Razi F Haq A Tonne P Logendran M
author_sort	Razi F
title	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
title_short	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
title_full	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
title_fullStr	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
title_full_unstemmed	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
title_sort	three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/68d1772552b340c8941b672531224913
work_keys_str_mv	AT razif threeyearfollowupofranibizumabtreatmentofwetagerelatedmaculardegenerationinfluenceofbaselinevisualacuityandinjectionfrequencyonvisualoutcomes AT haqa threeyearfollowupofranibizumabtreatmentofwetagerelatedmaculardegenerationinfluenceofbaselinevisualacuityandinjectionfrequencyonvisualoutcomes AT tonnep threeyearfollowupofranibizumabtreatmentofwetagerelatedmaculardegenerationinfluenceofbaselinevisualacuityandinjectionfrequencyonvisualoutcomes AT logendranm threeyearfollowupofranibizumabtreatmentofwetagerelatedmaculardegenerationinfluenceofbaselinevisualacuityandinjectionfrequencyonvisualoutcomes
_version_	1718401375123013632

Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes

Ejemplares similares